Liu Yin, Xu Hui-Fang, Zhang Xi, Yu Yan-Qin, Zhao Yu-Qian, Zhang Shao-Kai, Qiao You-Lin
Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital and Institute, Beijing, China.
BMJ Open. 2022 Mar 9;12(3):e054403. doi: 10.1136/bmjopen-2021-054403.
Colorectal cancer (CRC) is one of the most common cancers in China. Most patients have developed advanced stage at diagnosis, leading to a low 5-year survival rate. To optimise prevention strategies, we planned a survey to evaluate the disease knowledge, medical experience and health-related quality of life (HRQOL) before and after the treatment of CRC, and healthcare costs among patients with advanced CRC in China.
This is a nationwide, hospital-based, multicentre survey. Nineteen hospitals in seven cities were selected by multistage stratified sampling. Mainland China is divided into seven regions according to the traditional administrative district definition; two cities of each region were selected through simple random sampling, and then one tertiary cancer hospital and one general hospital were selected for each city. More than 4445 patients with CRC in the selected hospitals with stage III or IV will be enrolled in this study. The trained interviewers will collect information through patients' self-report and/or medical records, including demographics and medical history; knowledge about CRC high-risk factors, screening procedure and treatment methods; medical experience on CRC screening, diagnosis and treatment; HRQOL before and after CRC treatment; and costs of CRC. All data will be input by two independent staff and verified using Epidata V.3.1 software. Data validation plan will be made to guide data checking. All statistical analyses will be conducted using SAS V.9.4 and SPSS V.24.0 software.
The study was approved by the ethics committees of Henan Cancer Hospital, the leading participant hospital. Findings of this study will be disseminated through peer-reviewed open-access journals and presented as posters and/or oral sections in national and international conferences. Results will also be popularised to the public via media or the internet.
结直肠癌（CRC）是中国最常见的癌症之一。大多数患者在确诊时已发展至晚期，导致5年生存率较低。为优化预防策略，我们计划开展一项调查，以评估中国晚期结直肠癌患者在CRC治疗前后的疾病知识、就医经历和健康相关生活质量（HRQOL），以及医疗费用。
这是一项基于医院的全国性多中心调查。通过多阶段分层抽样选取了七个城市的19家医院。根据传统行政区划分，中国大陆分为七个地区；每个地区通过简单随机抽样选取两个城市，然后为每个城市选取一家三级肿瘤医院和一家综合医院。选定医院中分期为III期或IV期的4445多名CRC患者将纳入本研究。经过培训的访员将通过患者自我报告和/或病历收集信息，包括人口统计学和病史；关于CRC高危因素、筛查程序和治疗方法的知识；CRC筛查、诊断和治疗的就医经历；CRC治疗前后的HRQOL；以及CRC的费用。所有数据将由两名独立工作人员录入，并使用Epidata V.3.1软件进行核实。将制定数据验证计划以指导数据检查。所有统计分析将使用SAS V.9.4和SPSS V.24.0软件进行。
该研究已获得主要参与医院河南肿瘤医院伦理委员会的批准。本研究的结果将通过同行评审的开放获取期刊进行传播，并在国内和国际会议上以海报和/或口头报告的形式展示。结果还将通过媒体或互联网向公众普及。
